Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.42 |
| ▸ | BTK | Q06187 | 3/20 | 0.42 |
| ▸ | LPL | P06858 | 8/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.39 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PNMT | P11086 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30550009 | 1.00 | JAK2 (0.42) | JAK2BTKLPLLIPGCYP2A13 | |
| SCHEMBL24773231 | 0.90 | LPL (0.42) | JAK2BTKLPLLIPGEGFR | |
| SCHEMBL20540203 | 0.85 | LPL (0.39) | JAK2BTKLPLLIPGEGFR | |
| SCHEMBL29993417 | 0.84 | JAK2 (0.39) | JAK2BTKLPLLIPGALDH1A1 | |
| SCHEMBL10041652 | 0.84 | LPL (0.46) | JAK2BTKLPLLIPGTSHR | |
| SCHEMBL10325869 | 0.83 | JAK2 (0.39) | JAK2BTKLPLLIPGEGFR | |
| SCHEMBL16815466 | 0.83 | JAK2 (0.53) | JAK2BTKLPLLIPGEGFR | |
| SCHEMBL22208077 | 0.81 | JAK2 (0.41) | JAK2BTKLPLLIPGTSHR | |
| SCHEMBL8258588 | 0.81 | JAK2 (0.41) | JAK2BTKLPLLIPGCYP2A13 | |
| SCHEMBL23045909 | 0.81 | JAK2 (0.41) | JAK2BTKLPLLIPGEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154107-A1 | 3,4-Dihydroisoquinolin-1(2H)-Ones Derivatives as STING Antagonists and the Use Thereof | BEIGENE SWITZERLAND GMBH (CH) | 2025-05-15 | — | — | US | disclosed |
| WO-2022033430-A1 | HETEROTRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 深圳微芯生物科技股份有限公司 | 2022-02-17 | — | — | WO | disclosed |
| US-9617228-B2 | Oligomer-containing substituted aromatic triazine compounds | NEKTAR THERAPEUTICS (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617228-B2 | Oligomer-containing substituted aromatic triazine compounds | NEKTAR THERAPEUTICS (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617228-B2 | Oligomer-containing substituted aromatic triazine compounds | NEKTAR THERAPEUTICS (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160194294-A1 | OLIGOMER-CONTAINING SUBSTITUTED AROMATIC TRIAZINE COMPOUNDS | NEKTAR THERAPEUTICS | 2016-07-07 | — | — | US | disclosed |
| US-20160194294-A1 | OLIGOMER-CONTAINING SUBSTITUTED AROMATIC TRIAZINE COMPOUNDS | NEKTAR THERAPEUTICS | 2016-07-07 | — | — | US | disclosed |
| US-20160194294-A1 | OLIGOMER-CONTAINING SUBSTITUTED AROMATIC TRIAZINE COMPOUNDS | NEKTAR THERAPEUTICS | 2016-07-07 | — | — | US | disclosed |
| US-9266845-B2 | Oligomer-containing substituted aromatic triazine compounds | NEKTAR THERAPEUTICS (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266845-B2 | Oligomer-containing substituted aromatic triazine compounds | NEKTAR THERAPEUTICS (US) | 2016-02-23 | — | — | US | disclosed |
| US-20140256732-A1 | OLIGOMER-CONTAINING SUBSTITUTED AROMATIC TRIAZINE COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2014-09-11 | — | — | US | disclosed |
| US-8772479-B2 | Oligomer-containing substituted aromatic triazine compounds | NEKTAR THERAPEUTICS (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772479-B2 | Oligomer-containing substituted aromatic triazine compounds | NEKTAR THERAPEUTICS (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772479-B2 | Oligomer-containing substituted aromatic triazine compounds | NEKTAR THERAPEUTICS (US) | 2014-07-08 | — | — | US | disclosed |
| US-20120122871-A1 | Oligomer-Containing Substituted Aromatic Triazine Compounds | NEKTAR THERAPEUTICS (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122871-A1 | Oligomer-Containing Substituted Aromatic Triazine Compounds | NEKTAR THERAPEUTICS (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122871-A1 | Oligomer-Containing Substituted Aromatic Triazine Compounds | NEKTAR THERAPEUTICS (US) | 2012-05-17 | — | — | US | disclosed |
| EP-2430003-A1 | OLIGOMER-CONTAINING SUBSTITUTED AROMATIC TRIAZINE COMPOUNDS | Nektar Therapeutics (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010132691-A1 | OLIGOMER-CONTAINING SUBSTITUTED AROMATIC TRIAZINE COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132691-A1 | OLIGOMER-CONTAINING SUBSTITUTED AROMATIC TRIAZINE COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122871-A1 | Oligomer-Containing Substituted Aromatic Triazine Compounds | NOD2, HTT, CUL5 | JAK2 1387/4885BTK 3543/4885LPL 4671/4885 |
| US-20140256732-A1 | OLIGOMER-CONTAINING SUBSTITUTED AROMATIC TRIAZINE COMPOUNDS | NOD2, HTT, IPO5 | JAK2 1081/4885BTK 2842/4885LPL 4272/4885 |
| US-20160194294-A1 | OLIGOMER-CONTAINING SUBSTITUTED AROMATIC TRIAZINE COMPOUNDS | NOD2, HTT, IPO5 | JAK2 1081/4885BTK 2842/4885LPL 4272/4885 |
| US-20250154107-A1 | 3,4-Dihydroisoquinolin-1(2H)-Ones Derivatives as STING Antagonists and the Use Thereof | STING1, IRF3, MAVS | JAK2 1426/4885BTK 115/4885LPL 2932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.